Opinion

Video

Evaluating Quality of Life and Adherence With mCRC Treatment Options

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD

Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.

Video content above is prompted by the following:

  1. What has been your experience with the impact of these third-line therapy options (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on a patient’s quality of life?
  2. What insights can you share related to patient adherence with third-line therapies in metastatic colorectal cancer?
Related Videos
1 expert is featured in this series.
Dr Rebecca Haberman
5 experts are featured in this series.
5 experts are featured in this series.
Katie Abouzahr, MD
Dr Rebecca Haberman
Related Content
AChR-Ab titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study. | Image credit: luchschenF - stock.adobe.com
February 21st 2025

AChR-Ab Titers Associated With Myasthenia Gravis Severity

Rose McNulty
Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Doctor examines hologram of female uterus | Image Credit: WS Studio 1985 - stock.adobe.com
February 20th 2025

Abortion in 2025: Access, Fertility, and Infant Mortality Updates

Giuliana Grossi
While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Noelle LoConte, MD | Image credit: University of Wisconsin
February 19th 2025

What Recent Evidence Is Telling Us About Alcohol and Cancer

Produced by Mary Caffrey
Evidence shows alcohol increases estrogen, raising breast cancer risk, with pandemic-related consumption spikes among women.
Female patient drinking water and eating healthy | Image Credit: Viacheslav Yakobchuk - stock.adobe.com
February 18th 2025

Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status

Brooke McCormick
In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected overall survival but not progression-free survival.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo